Takeda Pharmaceutical Company — Ethics Grade B-

Takeda Pharmaceutical Company receives an overall ethics grade of B- (68/100) on CancelCo's corporate accountability database. Sector: Healthcare. Market cap: Large Cap.

Category scores

• labor: 75
• privacy: 88
• consumer: 50
• environment: 80
• humanRights: 82

Documented incidents (3)

• Actos Bladder Cancer Cover-up (high, 2015) — Takeda agreed to pay billions to settle claims that it hid the bladder cancer risks associated with its diabetes drug, Actos, while marketing it to patients.
• Kickbacks Settlement (medium, 2020) — A Takeda subsidiary settled allegations that it used a foundation as a conduit to pay illegal kickbacks to cover Medicare patients' co-pays to induce them to use the drug Cuprimine.
• Vaccine Contamination (medium, 2021) — Takeda had to suspend the use of millions of doses of a COVID-19 vaccine in Japan after stainless steel contaminants were found in vials produced by an contract manufacturer.

Documented good deeds

• Access to Medicine Leader — Takeda is consistently ranked in the top 10 of the Access to Medicine Index for its efforts to provide therapies to low-and-middle-income countries.

Ethical alternatives

• Gilead Sciences — Better transparency scores in product safety and lower frequency of major litigation regarding drug risk suppression.